Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Anetumab ravtansine + Bevacizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anetumab ravtansine||BAY94-9343||Anetumab ravtansine is a monoclonal antibody against mesothelin (MSLN) in conjugation with maytansinoid DM4, which delivers maytansinoid DM4 to tumor cells over expressing mesothelin, resulting in tumor cell death (PMID: 24714131).|
|Bevacizumab||Avastin||VEGF Antibody 11 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03587311||Phase II||Anetumab ravtansine + Bevacizumab Bevacizumab + Paclitaxel||Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Recruiting|